IMUNON Email Formats

Biotechnology Research • Lawrence, New Jersey, United States • 21-50 Employees

IMUNON Email Formats

IMUNON uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@imunon.com), used 66.7% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@imunon.com	66.7%
{first name}{last name}	johndoe@imunon.com	16.7%
{first initial}{last name}{last name}	jdoedoe@imunon.com	8.3%
{last name}{last name}	doedoe@imunon.com	8.3%

Key Contacts at IMUNON

Lauren Musso

Senior Director, Clinical Operations

Jeff Sparks

Senior Director, Process Development & Clinical Manufacturing

Subeena Sood

Associate Director

Company overview

Headquarters	997 Lenox Drive, Suite 100, Lawrenceville, New Jersey 08648, US
Phone number	+16098969100
Website	imunon.com
Employees	21-50
Socials

About IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNON’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.